Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
American Health & Drug Benefits|October 1, 2016
Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United StatesS Pinar Bilir, Qiufei Ma, Zhongyun Zhao, et al.
The American Journal of Managed Care|August 30, 2021
Cost-effectiveness of intensification with SGLT2 inhibitors for type 2 diabetesManjiri Pawaskar, S Pinar Bilir, Stacey Kowal, et al.
European Endocrinology|October 24, 2018
Cost-effectiveness Analysis of a Flash Glucose Monitoring System for Patients with Type 1 Diabetes Receiving Intensive Insulin Treatment in SwedenS Pinar Bilir, Richard Hellmund, Beth Wehler, et al.
American Journal of Clinical Oncology|June 21, 2021
Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United StatesJesse Sussell, Gurleen Singh Jhuti, Vincent Antao, et al.
Current Medical Research and Opinion|September 7, 2019
Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United StatesPatrick W Sullivan, Qianyi Li, S Pinar Bilir, et al.
The American Journal of Managed Care|May 18, 2021
US cost-effectiveness and budget impact of point-of-care NAAT for streptococcusS Pinar Bilir, Eliza Kruger, Mathilde Faller, et al.
Plos One|November 8, 2019
Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent productDeborah M Anderson, Veena R Kumar, Diana L Arper, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 13, 2026
Cost-Effectiveness of Automated Blood Culture Systems: Comparison of BACT/ALERT VIRTUO and BD BACTEC FX from a Provider PerspectivePallavi Krishnamurthy, Pablo Anaya, S Pinar Bilir, et al.
Frontiers in Immunology|June 10, 2024
Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United StatesOlalekan O Oluwole, Markqayne D Ray, Richard M Zur, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 29, 2025
Estimating the economic consequences of leveraging the novel cobas® HIV-1/HIV-2 Qualitative NAT Test in routine HIV testingS Pinar Bilir, Pallavi Krishnamurthy, James K Karichu, et al.
Pageof 3